Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the company's new chief medical officer, richard markus, m.d., ph.d., the compensation committee of the company's board of directors granted dr. markus an option to purchase 305,328 shares of the company's common stock.
RCUS Ratings Summary
RCUS Quant Ranking